215 related articles for article (PubMed ID: 31517438)
1. Iron chelation and 2-oxoglutarate-dependent dioxygenase inhibition suppress mantle cell lymphoma's cyclin D1.
Babosova O; Kapralova K; Raskova Kafkova L; Korinek V; Divoky V; Prchal JT; Lanikova L
J Cell Mol Med; 2019 Nov; 23(11):7785-7795. PubMed ID: 31517438
[TBL] [Abstract][Full Text] [Related]
2. Prolyl hydroxylation by EglN2 destabilizes FOXO3a by blocking its interaction with the USP9x deubiquitinase.
Zheng X; Zhai B; Koivunen P; Shin SJ; Lu G; Liu J; Geisen C; Chakraborty AA; Moslehi JJ; Smalley DM; Wei X; Chen X; Chen Z; Beres JM; Zhang J; Tsao JL; Brenner MC; Zhang Y; Fan C; DePinho RA; Paik J; Gygi SP; Kaelin WG; Zhang Q
Genes Dev; 2014 Jul; 28(13):1429-44. PubMed ID: 24990963
[TBL] [Abstract][Full Text] [Related]
3. Control of cyclin D1 and breast tumorigenesis by the EglN2 prolyl hydroxylase.
Zhang Q; Gu J; Li L; Liu J; Luo B; Cheung HW; Boehm JS; Ni M; Geisen C; Root DE; Polyak K; Brown M; Richardson AL; Hahn WC; Kaelin WG; Bommi-Reddy A
Cancer Cell; 2009 Nov; 16(5):413-24. PubMed ID: 19878873
[TBL] [Abstract][Full Text] [Related]
4. Mechanism of the antitumoral activity of deferasirox, an iron chelation agent, on mantle cell lymphoma.
Vazana-Barad L; Granot G; Mor-Tzuntz R; Levi I; Dreyling M; Nathan I; Shpilberg O
Leuk Lymphoma; 2013 Apr; 54(4):851-9. PubMed ID: 23020673
[TBL] [Abstract][Full Text] [Related]
5. Deferasirox induces cyclin D1 degradation and apoptosis in mantle cell lymphoma in a reactive oxygen species- and GSK3β-dependent mechanism.
Samara A; Shapira S; Lubin I; Shpilberg O; Avigad S; Granot G; Raanani P
Br J Haematol; 2021 Feb; 192(4):747-760. PubMed ID: 33521925
[TBL] [Abstract][Full Text] [Related]
6. Edging toward new therapeutics with cyclin D1 Egl'ng on cancer.
Dang CV
Cancer Cell; 2009 Nov; 16(5):361-2. PubMed ID: 19878865
[TBL] [Abstract][Full Text] [Related]
7. Over-expression of prolyl hydroxylase-1 blocks NF-κB-mediated cyclin D1 expression and proliferation in lung carcinoma cells.
Xie X; Xiao H; Ding F; Zhong H; Zhu J; Ma N; Mei J
Cancer Genet; 2014 May; 207(5):188-94. PubMed ID: 24935227
[TBL] [Abstract][Full Text] [Related]
8. Cyclin D1-CDK4 activity drives sensitivity to bortezomib in mantle cell lymphoma by blocking autophagy-mediated proteolysis of NOXA.
Heine S; Kleih M; Giménez N; Böpple K; Ott G; Colomer D; Aulitzky WE; van der Kuip H; Silkenstedt E
J Hematol Oncol; 2018 Sep; 11(1):112. PubMed ID: 30180865
[TBL] [Abstract][Full Text] [Related]
9. 2-oxoglutarate analogue inhibitors of HIF prolyl hydroxylase.
Mole DR; Schlemminger I; McNeill LA; Hewitson KS; Pugh CW; Ratcliffe PJ; Schofield CJ
Bioorg Med Chem Lett; 2003 Aug; 13(16):2677-80. PubMed ID: 12873492
[TBL] [Abstract][Full Text] [Related]
10. Suberoylanilide hydroxamic acid (SAHA; vorinostat) suppresses translation of cyclin D1 in mantle cell lymphoma cells.
Kawamata N; Chen J; Koeffler HP
Blood; 2007 Oct; 110(7):2667-73. PubMed ID: 17606765
[TBL] [Abstract][Full Text] [Related]
11. Selective inhibition of hypoxia-inducible factor (HIF) prolyl-hydroxylase 1 mediates neuroprotection against normoxic oxidative death via HIF- and CREB-independent pathways.
Siddiq A; Aminova LR; Troy CM; Suh K; Messer Z; Semenza GL; Ratan RR
J Neurosci; 2009 Jul; 29(27):8828-38. PubMed ID: 19587290
[TBL] [Abstract][Full Text] [Related]
12. Nonantibiotic Effects of Fluoroquinolones in Mammalian Cells.
Badal S; Her YF; Maher LJ
J Biol Chem; 2015 Sep; 290(36):22287-97. PubMed ID: 26205818
[TBL] [Abstract][Full Text] [Related]
13. Cyclin D1 depletion induces DNA damage in mantle cell lymphoma lines.
Mohanty S; Mohanty A; Sandoval N; Tran T; Bedell V; Wu J; Scuto A; Murata-Collins J; Weisenburger DD; Ngo VN
Leuk Lymphoma; 2017 Mar; 58(3):676-688. PubMed ID: 27338091
[TBL] [Abstract][Full Text] [Related]
14. Intermediary metabolite precursor dimethyl-2-ketoglutarate stabilizes hypoxia-inducible factor-1α by inhibiting prolyl-4-hydroxylase PHD2.
Hou P; Kuo CY; Cheng CT; Liou JP; Ann DK; Chen Q
PLoS One; 2014; 9(11):e113865. PubMed ID: 25420025
[TBL] [Abstract][Full Text] [Related]
15. Hydroxylation of hypoxia-inducible transcription factors and chemical compounds targeting the HIF-alpha hydroxylases.
Bruegge K; Jelkmann W; Metzen E
Curr Med Chem; 2007; 14(17):1853-62. PubMed ID: 17627521
[TBL] [Abstract][Full Text] [Related]
16. Antitumoral activity of lenalidomide in in vitro and in vivo models of mantle cell lymphoma involves the destabilization of cyclin D1/p27KIP1 complexes.
Moros A; Bustany S; Cahu J; Saborit-Villarroya I; Martínez A; Colomer D; Sola B; Roué G
Clin Cancer Res; 2014 Jan; 20(2):393-403. PubMed ID: 24178620
[TBL] [Abstract][Full Text] [Related]
17. Endogenous 2-oxoglutarate levels impact potencies of competitive HIF prolyl hydroxylase inhibitors.
Thirstrup K; Christensen S; Møller HA; Ritzén A; Bergström AL; Sager TN; Jensen HS
Pharmacol Res; 2011 Sep; 64(3):268-73. PubMed ID: 21504793
[TBL] [Abstract][Full Text] [Related]
18. A cyclin-D1 interaction with BAX underlies its oncogenic role and potential as a therapeutic target in mantle cell lymphoma.
Beltran E; Fresquet V; Martinez-Useros J; Richter-Larrea JA; Sagardoy A; Sesma I; Almada LL; Montes-Moreno S; Siebert R; Gesk S; Calasanz MJ; Malumbres R; Rieger M; Prosper F; Lossos IS; Piris MA; Fernandez-Zapico ME; Martinez-Climent JA
Proc Natl Acad Sci U S A; 2011 Jul; 108(30):12461-6. PubMed ID: 21746927
[TBL] [Abstract][Full Text] [Related]
19. Iron chelation regulates cyclin D1 expression via the proteasome: a link to iron deficiency-mediated growth suppression.
Nurtjahja-Tjendraputra E; Fu D; Phang JM; Richardson DR
Blood; 2007 May; 109(9):4045-54. PubMed ID: 17197429
[TBL] [Abstract][Full Text] [Related]
20. No evidence of cell cycle dysregulation in mantle cell lymphoma in vivo.
Vogt N; Abramov D; Koch K; Masqué-Soler N; Szczepanowski M; Klapper W
Leuk Lymphoma; 2015 Jul; 56(7):2134-40. PubMed ID: 25315075
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
